Results 31 to 40 of about 6,343 (174)

Mesalamine induced hepatotoxicity. Is mesalamine safe?

Revista Española de Enfermedades Digestivas
Mesalamine is a medication used widely in the treatment of patients with inflammatory bowel disease. Although mesalamine is considered safe, hepatotoxicity has been reported with an incidence of 0-4%. We present the clinical picture of a patient with hepatotoxicity due to mesalamine.
Javier, Pérez-Valenzuela, Lorena, Castro Solari, Rodrigo, Quera, Luis, Contreras   +3 more
openaire   +2 more sources

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab

Pediatric Dermatology, EarlyView.
ABSTRACT Bowel‐associated dermatosis‐arthritis syndrome (BADAS) is a rare neutrophilic dermatosis characterized by recurrent fever, arthralgias, and skin eruptions, most commonly occurring in patients with inflammatory bowel disease. We report the case of a 17‐year‐old female with Crohn's disease who developed BADAS and achieved complete and durable ...
Kylie E. Peake, Harman Toor, Marie‐Christine Jean, Collin C. Barker, Joseph M. Lam   +4 more
wiley   +1 more source

The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.

PLoS ONE, 2014
UnlabelledThe anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and ...
Ma Somsouk, Richard M Dunham, Michelle Cohen, Rebecca Albright, Mohamed Abdel-Mohsen, Teri Liegler, Jeffrey Lifson, Michael Piatak, Robert Gorelick, Yong Huang, Yuaner Wu, Priscilla Y Hsue, Jeffrey N Martin, Steven G Deeks, Joseph M McCune, Peter W Hunt   +15 more
doaj   +1 more source

Case Report of a Rapidly Progressive Indolent T‐Cell Lymphoma of the Gastrointestinal Tract

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Indolent T‐cell lymphoma of the gastrointestinal tract (iTCL‐GI) is a relatively newly recognized disease entity. iTCL‐GI was first proposed by Perry et al. in 2013, before it was formally incorporated as a distinct disease category in the fifth edition of the World Health Organization Classification of Hematolymphoid Tumors: Lymphoid ...
Keitaro Shibuya, Akiko Tamura, Daiki Yafuso, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Toshimitsu Fujii, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
wiley   +1 more source

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Clinical Pharmacology: Advances and Applications, 2019
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg ...
Jakate A, McNamee B, Burkindine D
doaj  

Efficacy and Tolerance of 5-Aminosalicylic Acid Suppositories in the Treatment of Ulcerative Proctitis: A Review of Two Double-Blind, Placebo Controlled Trials

Canadian Journal of Gastroenterology, 1990
The efficacy and tolerance of 500 mg 5-aminosalicylic acid (mesalamine) suppositories in the treatment of ulcerative proctitis were assessed in two double-blind, placebo controlled studies of six weeks' duration, involving a total of 173 patients.
CN Williams
doaj   +1 more source

A Randomized Single Blind Parallel Group Study Comparing Monoherbal Formulation Containing Holarrhena antidysenterica Extract with Mesalamine in Chronic Ulcerative Colitis Patients

Ancient Science of Life, 2016
Background: Incidences of side effects and relapses are very common in chronic ulcerative colitis patients after termination of the treatment. Aims and Objectives: This study aims to compare the treatment with monoherbal formulation of Holarrhena ...
Sarika Johari, Tejal Gandhi
doaj   +1 more source

One of the 5-aminosalicylates drug, mesalamine as a drug repurposing lead against breast cancer

Bulletin of the National Research Centre, 2022
Background Breast cancer is the world's second leading cause of death in women. The problem of chemoresistance in breast cancer is proving to be a challenge for researchers and several oncologists all around the world.
Dayanand Swami, Shafina Siddiqui, Urwashi Kumar, Shine Devarajan, Jyotirmoi Aich   +4 more
doaj   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu, Ji Eun Ryoo, Brian S. Henick, Adam Mor   +3 more
wiley   +1 more source

Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database

BMC Gastroenterology, 2013
Background Although high non-adherence to medication has been noticed for ulcerative colitis (UC), little is known about adherence to mesalamine treatments and determinants that can predict adherence.
Lachaine Jean, Yen Linnette, Beauchemin Catherine, Hodgkins Paul   +3 more
doaj   +1 more source